CYP2C9 Variants Linked to Clinical Events in VTE

This article originally appeared here.
Share this content:
<i>CYP2C9</i> Variants Linked to Clinical Events in VTE
CYP2C9 Variants Linked to Clinical Events in VTE

TUESDAY, Sept. 5, 2017 (HealthDay News) -- For elderly patients treated with vitamin K antagonists for venous thromboembolism (VTE), CYP2C9 variants are associated with any clinical event, according to a study published online Aug. 22 in the Journal of Thrombosis and Haemostasis.

Michael Nagler, M.D., from Bern University Hospital in Switzerland, and colleagues examined the correlation between CYP2C9/VKORC1 variants and long-term clinical outcomes among 774 elderly patients treated with vitamin K antagonists for VTE.

Overall, 78 percent of the patients had a CYP2C9 or VKORC1 variant. The researchers found that 43.2 percent of patients had any clinical event, 15.4 percent died, 12.9 and 21.6 percent had major and non-major bleeding, respectively, and 12.9 percent had recurrent VTE. After adjustment there was a correlation for CYP2C9 variants with any clinical event (hazard ratio, 1.34; 95 percent confidence interval, 1.08 to 1.66), death (hazard ratio, 1.74; 95 percent confidence interval, 1.19 to 2.52), and clinically relevant non-major bleeding (subhazard ratio, 1.39; 95 percent confidence interval, 1.02 to 1.89), but not with major bleeding (subhazard ratio, 1.03; 95 percent confidence interval, 0.69 to 1.55) or recurrent VTE (subhazard ratio, 0.95; 95 percent confidence interval, 0.62 to 1.44). Slightly lower anticoagulation quality was seen for patients with genetic variants.

"CYP2C9 was associated with long-term overall mortality and non-major bleeding," the authors write. "While genetic variants were associated with a slightly lower anticoagulation quality, there was no relationship between genetic variants and major bleeding or VTE recurrence."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »